Table 3.
Clinical Outcomes According to Presence of INOCA or CMD
| No INOCA | INOCA | Multivariable* HR (95% CI) | P value | No CMD | CMD | Multivariable* HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|---|
| Total (N=287) | n=206 | n=81 | n=157 | n=130 | ||||
| All cause death | 11 (7.6%) | 4 (10.3%) | 1.30 (0.39–4.33) | 0.666 | 5 (4.3%) | 10 (14.4%) | 2.21 (0.72–6.80) | 0.165 |
| Cardiac death | 8 (5.4%) | 3 (7.2%) | 1.39 (0.35–5.55) | 0.640 | 3 (2.4%) | 8 (11.1%) | 3.05 (0.77–12.13) | 0.114 |
| Target‐vessel MI | 1 (0.8%) | 2 (2.6%) | 0.87 (0.61–160.44) | 0.108 | 3 (2.5%) | 0 (0%) | NA | 0.998 |
| Any revascularization | 13 (7.0%) | 7 (10.9%) | 1.47 (0.56–3.84) | 0.434 | 5 (3.7%) | 15 (12.7%) | 3.70 (1.34–10.25) | 0.012 |
| TVR † | 8 (4.4%) | 6 (9.8%) | 1.85 (0.60–5.68) | 0.285 | 3 (2.5%) | 11 (9.1%) | 4.26 (1.18–15.39) | 0.027 |
| Non‐TVR | 5 (2.7%) | 1 (1.2%) | 0.67 (0.76–5.85) | 0.713 | 2 (1.3%) | 4 (3.9%) | 2.75 (0.50–15.21) | 0.246 |
| MACE ‡ | 22 (13.2%) | 11 (20.1%) | 1.45 (0.68–3.09) | 0.340 | 10 (7.8%) | 23 (24.0%) | 2.97 (1.39–6.34) | 0.005 |
The cumulative incidences of clinical outcomes were presented as Kaplan‒Meier estimates during the median follow‐up of 1194.0 days (Q1–Q3, 730.0–1826.0 days). CMD indicates coronary microvascular disease; HR, hazard ratio; INOCA, ischemia with no obstructive coronary artery disease; MACE, major adverse cardiovascular events; MI, myocardial infarction; NA, not applicable; PCI, percutaneous coronary intervention; and TVR, target vessel revascularization.
Adjusted for age, sex, diabetes, hyperlipidemia, and previous percutaneous coronary intervention.
Defined as clinically driven revascularization of the target vessel by means of coronary bypass grafting or percutaneous coronary intervention.
Defined as the composite of all‐cause death, acute myocardial infarction not clearly attributable to a nontarget vessel, and any revascularization by means of coronary bypass grafting or percutaneous coronary intervention.